Article Text

Download PDFPDF
Tyrosine kinase inhibitors for metastatic renal cell carcinoma
  • Relevant BNF section: BNF 8.1.5


Renal cell carcinoma accounts for 2–3% of all adult malignancies worldwide, and around 30% of patients with the condition present with advanced or metastatic disease.1,2 Until recently, cytokine therapy (e.g. interleukin-2 or interferon-alfa) was the standard treatment for metastatic renal cell carcinoma but provided only a small survival advantage (e.g. extending life by a median of 2.5 months).3 A key development has been the introduction of drugs known as receptor tyrosine kinase inhibitors, which include ▼sunitinib (Sutent – Pfizer), ▼sorafenib (Nexavar – Bayer) and ▼pazopanib (Votrient – GlaxoSmithKline). Here we review the evidence on the efficacy, tolerability and cost-effectiveness of these treatments in renal cell carcinoma.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

  • Relevant BNF section: BNF 8.1.5

View Full Text